ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.065
-0.045 (-4.05%)
Jul 31, 2026, 2:51 PM EDT - Market open
ADC Therapeutics Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, ADC Therapeutics stock has a consensus rating of "Buy" and an average price target of $5.00. The average 1-year stock price forecast is 369.48% higher than the current stock price, while the lowest is $2.00 (+87.79%) and the highest is $10 (+838.97%).
Price Target: $5.00 (+369.48%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for ADC Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $2 | Hold | Maintains | $2 | +87.79% | Jul 7, 2026 |
| Guggenheim | Guggenheim | Buy Initiates $10 | Buy | Initiates | $10 | +838.97% | Jul 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Downgrades n/a | Hold | Downgrades | n/a | n/a | Jun 8, 2026 |
| Stephens | Stephens | Buy Reiterates $5 | Buy | Reiterates | $5 | +369.48% | Jun 4, 2026 |
Financial Forecast
Revenue This Year
80.89M
from 81.36M
Decreased by -0.57%
Revenue Next Year
123.82M
from 80.89M
Increased by 53.07%
EPS This Year
1.02
EPS Next Year
2.27
from 1.02
Increased by 122.55%
EPS and Forward PE are based on non-GAAP adjusted numbers.